Linvoseltamab

ATC Code L01FX37

Linvoseltamab

Definition

A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

Also known as Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5458, Anti-BCMA/CD3 Bispecific Antibody REGN5458, BCMA x CD3 Bispecific Antibody REGN5458, LINVOSELTAMAB, Linvoseltamab-gcpt, Lynozyfic, REGN 5458, REGN-5458, REGN5458 — per NCIT

Also identified as

Indications

Disease Relation Source
Multiple myeloma may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Lymphoid system may treat a disease of this organ DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.